Vivoryon Therapeutics NV (VVY) NPV

Sell:€2.03Buy:€2.05No change

Prices delayed by at least 15 minutes
Sell:€2.03
Buy:€2.05
Change:No change
Prices delayed by at least 15 minutes
Sell:€2.03
Buy:€2.05
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Vivoryon Therapeutics NV is a Germany-based clinical-stage biopharmaceutical company with focus on the research and development of new therapeutic products for the treatment of Alzheimer’s disease (AD) and other diseases with high medical need like Cancer and Fibrosis. The Company is developing a directed pipeline of product candidates with the project being a therapeutic approach for the treatment of AD. Its operations focus on the discovery and development of therapeutic programs, whereas operational research and development work is mainly outsourced to respective professional contract research organizations (CROs) or academic collaboration partners. Vivoryon strives to generate future revenues from licensing its product candidates to biopharmaceutical companies after development steps have been achieved or by commercializing products.

Key people

Frank Weber
Chief Executive Officer, Executive Director, Chief Medical Officer
Anne Doering
Chief Financial Officer, Executive Director
Michael Schaeffer
Chief Business Officer, Executive Director
Erich M. O. Platzer
Non-Executive Independent Chairman of the Board
Charlotte Lohmann
Non-Executive Independent Director
Claudia Riedl
Non-Executive Independent Director
Samir Shah
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Germany
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    NL00150002Q7
  • Market cap
    €53.44m
  • Employees
    15
  • Shares in issue
    26.07m
  • Exchange
    Euronext Amsterdam Stock Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.